Correction: EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells

Published Erratum

Honami Takada et al. PLoS One. 2017.

. 2017 Aug 1;12(8):e0182682.

doi: 10.1371/journal.pone.0182682. eCollection 2017.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0174136.].

EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, Uota S, Yamaoka S, Koyama T, Shimizu N, Yamamoto K, Fujiwara S, Miura O, Arai A. Takada H, et al. PLoS One. 2017 Mar 27;12(3):e0174136. doi: 10.1371/journal.pone.0174136. eCollection 2017. PLoS One. 2017. PMID: 28346502 Free PMC article.

Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.
Yoshimori M, Shibayama H, Imadome KI, Kawano F, Ohashi A, Nishio M, Shimizu N, Kurata M, Fujiwara S, Arai A. Yoshimori M, et al. Blood Adv. 2021 Apr 13;5(7):1805-1815. doi: 10.1182/bloodadvances.2020002417. Blood Adv. 2021. PMID: 33787860 Free PMC article.
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.
Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, Ito Y, Fukuhara N, Hirose A, Takeda Y, Makita M, Endo T, Kimura SI, Ishimura M, Miura O, Ohga S, Kimura H, Fujiwara S, Arai A. Yonese I, et al. Blood Adv. 2020 Jul 14;4(13):2918-2926. doi: 10.1182/bloodadvances.2020001451. Blood Adv. 2020. PMID: 32598475 Free PMC article.

1. Takada H, Imadome K-I, Shibayama H, Yoshimori M, Wang L, Saitoh Y, et al. (2017) EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells. PLoS ONE 12(3): e0174136 https://doi.org/10.1371/journal.pone.0174136 - DOI - PMC - PubMed